About this trial
This prospective, multicenter study aims to evaluate the relevance of anti-CD146 autoantibodies (AACD146) as biological markers for the early diagnosis of pulmonary diseases related to occupational exposure to silica. Silica exposure is a recognized risk factor for fibrotic, inflammatory, and cancerous respiratory diseases. Currently, no specific biological marker exists. The hypothesis is that AACD146 reflects early effects of silica exposure. The study will include 110 participants divided into two groups (exposed vs. non-exposed) and will compare AACD146 prevalence according to exposure level and the presence of respiratory diseases.
Eligibility criteria
Qualifiers
Subject, male or female, aged 18 or over
Subject with low exposure to silica <0.1 mg/m3 in the course of their professional activity, quantified during an occupational health consultation using an employment-exposure matrix
Subjects capable of consenting to participate in the study by signing a written informed consent form
Subjects who are beneficiaries of or affiliated with a social security system
Disqualifiers
Minor subject
Subject refusing to undergo the examinations required by the protocol
Contraindications to respiratory function tests: Recent eye or throat surgery, recent myocardial infarction or pulmonary embolism, poorly controlled high blood pressure, recent pneumothorax.
Pregnant or breastfeeding women, patients under guardianship or curatorship, deprived of liberty
Trial design
Treatments tested in this trial
- Respiratory function testing
- blood sampling
- CT scan